Research suggests hospitalisation risk lower for Omicron UK data indicates the variant is less severe than Delta, though increased transmissibility and reduced vaccine efficacy remain major concerns.
New insight into vaccines’ protection against Delta deaths AstraZeneca and Pfizer offer at least 90% protection from death caused by the Delta variant of the SARS-CoV-2 virus, new international analysis suggests.
COVID-19 vaccination reduces household transmission up to 97% The new research findings also appear to be reflected by the recent downward trend in Australian locally acquired cases, a former World Health Organization epidemiologist says.
Clearer picture of long-term vaccine efficacy against severe COVID Major pre-print studies comparing multiple COVID vaccines have found their ability to protect against hospitalisation and death may begin to wane in the long term.
ACT latest jurisdiction to reduce AZ dosing interval The COVID outbreak in Canberra means people can get a second dose of AstraZeneca after 4–8 weeks. What does this mean for efficacy?
Current COVID vaccines could be ineffective by next year: epidemiologists New coronavirus variants emerging in global hotspots are likely to impact vaccine efficacy. What does this mean for Australia?
New considerations for GPs ahead of vaccine rollout Recent studies suggest some coronavirus variants may reduce vaccine efficacy rates. newsGP explores what this could mean for GPs.
Vaccine’s reduced efficacy against COVID variant ‘worrying’ South Africa has paused its rollout of the Oxford University/AstraZeneca coronavirus vaccine. What does this mean for Australia?
Novavax confirms efficacy against emerging coronavirus variants New data on Australia’s third vaccine candidate shows it is highly effective against most COVID-19 variants, which may prove crucial as production bottlenecks force delays among other options.